Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation

Blood

Volumn 125, Issue 18, 2015, Pages 2865-2874

  Cieri, Nicoletta ^a,b   Oliveira, Giacomo ^a,b   Greco, Raffaella ^a,b   Forcato, Mattia ^c   Taccioli, Cristian ^c   Cianciotti, Beatrice ^a   Valtolina, Veronica ^a,d   Noviello, Maddalena ^a   Vago, Luca ^a   Bondanza, Attilio ^a,b   Lunghi, Francesca ^a   Marktel, Sarah ^a   Bellio, Laura ^a   Bordignon, Claudio ^b,d   Bicciato, Silvio ^c   Peccatori, Jacopo ^a   Ciceri, Fabio ^a   Bonini, Chiara ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d MOLMED S P A   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; CD31 ANTIGEN; CD45RA ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; FAS ANTIGEN; INTERLEUKIN 15; INTERLEUKIN 7; L SELECTIN; MYCOPHENOLATE MOFETIL; RAPAMYCIN; T LYMPHOCYTE RECEPTOR; TREOSULFAN;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FATE; CLINICAL ARTICLE; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOLOGICAL MEMORY; IN VIVO STUDY; LONGITUDINAL STUDY; LYMPHOCYTE DIFFERENTIATION; MEMORY T LYMPHOCYTE; MYELOABLATIVE CONDITIONING; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROGENY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; T LYMPHOCYTE SUBPOPULATION; TREATMENT DURATION; ALLOTRANSPLANTATION; BLOOD DONOR; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; HAPLOTYPE; IMMUNOLOGY; LYMPHOPOIESIS; METABOLISM; PHYSIOLOGY; T LYMPHOCYTE;

ADULT; ANTIGENS, CD31; BLOOD DONORS; CELL DIFFERENTIATION; CELL PROLIFERATION; HAPLOTYPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC MEMORY; LYMPHOPOIESIS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84928789921     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-11-608539     Document Type: Article

References (42)

1. Kaech SM, Cui W. Transcriptional control of effector and memory CD81 T cell differentiation. Nat Rev Immunol. 2012;12(11):749-761.
2. Jameson SC, Masopust D. Diversity in T cell memory: an embarrassment of riches. Immunity. 2009;31(6):859-871.
3. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401(6754):708-712.
4. Gattinoni L, Lugli E, Ji Y, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17(10):1290-1297.
5. Cieri N, CamisaB, Cocchiarella F, et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood. 2013;121(4):573-584.
6. Gerlach C, Rohr JC, Perié L, et al. Heterogeneous differentiation patterns of individual CD81 T cells. Science. 2013;340(6132):635-639.
7. Buchholz VR, Flossdorf M, Hensel I, et al. Disparate individual fates compose robust CD81 T cell immunity. Science. 2013;340(6132):630-635.
8. + T celldendritic cell interaction kinetics and memory fate decisions. Immunity. 2013;39(3):496-507.
9. Plumlee CR, Sheridan BS, Cicek BB, Lefrançois L. Environmental cues dictate the fate of individual CD81 T cells responding to infection. Immunity. 2013;39(2):347-356.
10. Graef P, Buchholz VR, Stemberger C, et al. Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(1) central memory T cells. Immunity. 2014;41(1):116-126.
11. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17): 1813-1826.
12. Luznik L, Fuchs EJ. High-dose, posttransplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res. 2010;47(1-3):65-77.
13. Fuchs EJ. Human leukocyte antigenhaploidentical stem cell transplantation using T-cell-replete bone marrow grafts. Curr Opin Hematol. 2012;19(6):440-447.
14. Robins HS, Campregher PV, Srivastava SK, et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood. 2009;114(19):4099-4107.
15. Yousfi Monod M, Giudicelli V, Chaume D, Lefranc MP. IMGT/JunctionAnalysis: the first tool for the analysis of the immunoglobulin and T cell receptor complex V-J and V-D-J JUNCTIONs. Bioinformatics. 2004;20(Suppl 1):i379-i385.
16. Krzywinski M, Schein J, Birol I, et al. Circos: an information aesthetic for comparative genomics. Genome Res. 2009;19(9):1639-1645.
17. Callan MF, Tan L, Annels N, et al. Direct visualization of antigen-specific CD81 T cells during the primary immune response to Epstein-Barr virus In vivo. J Exp Med. 1998;187(9): 1395-1402.
18. Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol. 2009;6(11): 638-647.
19. Jones RJ, Barber JP, Vala MS, et al. Assessment of aldehyde dehydrogenase in viable cells. Blood. 1995;85(10):2742-2746.
20. Kimmig S, Przybylski GK, Schmidt CA, et al. Two subsets of naive T helper cells with distinct T cell receptor excision circle content in human adult peripheral blood. J Exp Med. 2002;195(6): 789-794.
21. Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274(5284):94-96.
22. Doubrovina E, Carpenter T, Pankov D, Selvakumar A, Hasan A, O'Reilly RJ. Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(1) leukemias. Blood. 2012;120(8):1633-1646.
23. Kessler JH, Beekman NJ, Bres-Vloemans SA, et al. Efficient identification of novel HLA-A(∗) 0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med. 2001;193(1):73-88.
24. Fuji S, Kapp M, Einsele H. Alloreactivity of virusspecific T cells: possible implication of graftversus-host disease and graft-versus-leukemia effects. Front Immunol. 2013;4:330.
25. Felix NJ, Allen PM. Specificity of T-cell alloreactivity. Nat Rev Immunol. 2007;7(12): 942-953.
26. Kanakry CG, O'Donnell PV, Furlong T, et al. Multiinstitutional study of post-transplantation cyclophosphamide as single-agent graft-versushost disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014;32(31):3497-3505.
27. Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641-550.
28. Raiola AM, Dominietto A, Ghiso A, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant. 2013;19(1):117-122.
29. Bashey A, Zhang X, Sizemore CA, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol. 2013;31(10):1310-1316.
30. D'Orsogna LJ, Roelen DL, Doxiadis II, Claas FH. Alloreactivity from human viral specific memory T-cells. Transpl Immunol. 2010;23(4): 149-155.
31. Joshi NS, Cui W, Chandele A, et al. Inflammation directs memory precursor and short-lived effector CD8(1) T cell fates via the graded expression of T-bet transcription factor. Immunity. 2007;27(2): 281-295.
32. Yamane H, Paul WE. Cytokines of the g(c) family control CD41 T cell differentiation and function. Nat Immunol. 2012;13(11):1037-1044.
33. Zhang Y, Joe G, Hexner E, Zhu J, Emerson SG. Host-reactive CD81 memory stem cells in graftversus-host disease. Nat Med. 2005;11(12): 1299-1305.
34. Roberto A, Castagna L, Zanon V, et al. Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. Blood. 2015;125(18):2855-2864.
35. Akondy RS, Monson ND, Miller JD, et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD81 T cell response. J Immunol. 2009;183(12):7919-7930.
36. Yamanaka YJ, Gierahn TM, Love JC. The dynamic lives of T cells: new approaches and themes. Trends Immunol. 2013;34(2):59-66.
37. Champagne P, Ogg GS, King AS, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature. 2001;410(6824): 106-111.
38. Long HM, Chagoury OL, Leese AM, et al. MHC II tetramers visualize human CD41 T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response. J Exp Med. 2013; 210(5):933-949.
39. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD81 T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008; 118(1):294-305.
40. Buzon MJ, Sun H, Li C, et al. HIV-1 persistence in CD41 T cells with stem cell-like properties. Nat Med. 2014;20(2):139-142.
41. Wahren-Herlenius M, Dörner T. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet. 2013;382(9894): 819-831.
42. Cieri N, Mastaglio S, Oliveira G, Casucci M, Bondanza A, Bonini C. Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation. Immunol Rev. 2014;257(1):165-180.